

the amendments.

**The Response**

The Examiner has required restriction to one of the following inventions pursuant to 35 U.S.C. §§121 and 372:

- I. Claims 1-9, drawn to an OKT3 monoclonal antibody characterized by an exchange of cysteine at H100A and methods of producing said antibody.
- II. Claim 10, drawn to a method of use of the cysteine exchanged antibody in eliminating transplant rejection.
- III. Claim 11, drawn to a method of use of the cysteine exchanged antibody in tumor diagnosis.
- IV. Claim 11, drawn to a method of use of the cysteine exchanged antibody in tumor treatment.


In response to the Restriction Requirement, Applicants hereby elect the invention of Group I, Claims 1-9. Applicants expressly reserve the right to prosecute claims directed to the remaining allegedly distinct groups in one or more continuing or divisional applications.

**CONCLUSION**

Applicants believe that the application is in good and proper condition for allowance. Early notification of allowance is earnestly solicited. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is encouraged to call the undersigned at (650) 463-8109.

Respectfully submitted,

Date: March 6, 2001

  
Albert P. Halluin (Reg. No. 25,227)  
Viola T. Kung (Reg. No. 41,131)

**HOWREY SIMON ARNOLD & WHITE, LLP**  
301 Ravenswood Avenue  
Box 34  
Menlo Park, CA 94025  
(650) 463-8109